ACTRN12609000652279撤回1 期
Phase I study of the Safety and Tolerability of the Traditional Chinese Medicine formulation GOPAC in patients with advanced malignancy
适应症
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •* Active malignancy (recurrent or metastatic)
- •* can swallow capsules WHOLE
- •* Fluent english or chinese
- •* not currently receiving chemotherapy
排除标准
- •Inadequate organ function
- •Allergy to study ingredients (esp. mushrooms)
- •Eastern Cooperative Oncology performance group (ECOG PS) > 3
- •Concurrent radiotherapy
- •Major comorbidities
研究者
相似试验
招募中
1 期
utetium-177-anti-Programmed Cell Death-Ligand 1 single domain antibodies (177Lu-anti-PD-L1 sdAb) in metastatic non-small cell lung cancerMetastatic Non-small Cell Lung CancerCancer - Lung - Non small cellACTRN12623000959673Radiopharm Theranostics Ltd23
已完成
不适用
A phase I study of the safety, tolerability, and antitumor activity of escalating doses of combretastatin A4 phosphate given in combination with bevacizumab to subjects with advanced solid tumorsAdvanced solid tumoursSolid tumoursCancerISRCTN96787846OXiGENE, Inc. (USA)12
未知
1 期
Phase 1 Study of BMS-986148Solid tumorsJPRN-jRCT2080223357Bristol-Myers Squibb K.K.15
未知
1 期
Study of BMS-986012 in Subjects With Small Cell Lung CanerSmall Cell Lung CancerJPRN-jRCT2080223369Bristol-Myers Squibb K.K.18
已完成
1 期
Safety Study of BMS-986016 With or Without Nivolumab in Subjects With Advanced Solid TumorsAdvanced Solid TumorsJPRN-jRCT2080223428Bristol-Myers Squibb K.K.27